Canaccord Genuity Maintains Buy on Doximity, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Negative 48.1%

Neg 48.1% Neu 0% Pos 0%

Canaccord Genuity analyst Richard Close maintains Doximity (NYSE:DOCS) with a Buy and lowers the price target from $34 to $30.